AVERROES APIXABAN PDF
In patients with atrial fibrillation who were unable to receive warfarin for any reason, the use of apixaban reduced the risk of stroke and systemic embolism when compared to aspirin. Study Rundown: Atrial fibrillation is a common arrhythmia that increases the risk of stroke and. AVERROES has shown that the new oral anti-Xa inhibitor apixaban is superior to aspirin in terms of efficacy, with surprisingly similar safety. AVERROES. Apixaban Versus ASA. To Reduce the Risk Of Stroke. Coordinated by Population Health Research institute. Hamilton, Ontario, Canada. Sponsors.
|Published (Last):||7 February 2015|
|PDF File Size:||7.56 Mb|
|ePub File Size:||14.19 Mb|
|Price:||Free* [*Free Regsitration Required]|
VKA therapy not recommended by the physician; N Engl J Med ; Apixaban in Patients with Atrial Fibrillation.
There were 51 primary outcome events in those randomised to apixaban 1. N Engl J Med Strengths Strong points and important messages of the study are: A serious bleeding event during VKA therapy; 4.
Dabigatran versus warfarin in patients with atrial fibrillation. Notes to editor Correspondence: With a mean follow-up of 1. Concurrent medications whose metabolism could be affected by VKAs; 9.
AVERROES – Wiki Journal Club
Presented as apixaban vs. Patients were eligible if they were 50 years of age or older and if they had atrial fibrillation that had been documented in the 6 months prior to enrollment or by lead electrocardiography on the day of screening.
ESC sub specialties communities.
AVERROES on the other hand has shown that the new oral anti-Xa inhibitor apixaban is superior to aspirin in terms of efficacy, with surprisingly similar safety. This page was last modified on 3 Decemberat It has multiple theoretical benefits over VKA therapy including less intensive monitoring and fewer drug interactions.
Analyses are to time of first event. Connolly SJ, et al. J Am Coll Cardiol ; Of the patients enrolled, reasons for being deemed unsuitable for VKA therapy included the following: Assessment that patient would be unable or unlikely to adhere to restrictions on factors such as alcohol and diet; The median duration of follow-up was 1.
Views Read View source View history. To reduce the burden of cardiovascular disease.
The AVERROES Trial – Clinical Implications
All these reasons can be grouped in three broad categories: The primary outcome was stroke or systemic embolism. There were 44 1. The reasons apiaban VKA therapy was unsuitable for the patient had to be documented in the study case report forms. Yet, these proportions reflect the current underuse of Averroed in multiple registries. Sign in to My ESC. We will here briefly discuss the clinical implications of the trial. Assessment that INR could not or was unlikely to be measured at requested interval; 5.
apiaxban Based on the indirect comparison with ACTIVE A, one should conclude that apixaban is, at the time of writing, the best alternative to aspirin ever found in patients deemed unsuitable for VKAs. One may question each of these choices: The New England Journal of Medicine.
To get the best experience using our website we recommend that you upgrade to a newer version. Read your latest personalised notifications Sign in No account yet?
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. Mortality rates were 3. The trial was terminated early given a treatment benefit with apixaban. Apixaban is a novel oral anticoagulant that inhibits factor Xa. In patients with atrial fibrillation thought to be unsuitable candidates for anticoagulation with a vitamin K antagonist, apixaban signficantly reduced the risk of stroke and systemic embolism without increasing the apixxaban of major bleeding or intracranial hemorrhage when compared to aspirin.
Also, how does apixaban compare to aspirin rates of major bleeding? Patients also needed to have at least one of the following risk factors for stroke: Navigation menu Personal tools Create account Log in.